SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is seeing renewed interest as the community rallies behind anticipated network upgrades, burn initiatives, and a shared long-term belief in a potential reversal. Traders are actively discussing the token's low entry point and perceived recovery potential, while comparing its resilience to broader market movements.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention as investors react to a combination of institutional staking growth and anticipation surrounding potential regulatory developments. The community is actively debating the coin's long-term value, with active discussions focused on navigating market volatility while balancing sentiment between bullish price-appreciation narratives and concerns over liquidity shifts.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant buzz on social media as the Solana-based memecoin maintains steady community momentum and continues to feature prominently on trending lists. Enthusiasts are highlighting its long-term track record, locked liquidity, and ongoing community initiatives like poker nights to foster engagement and promote the project.

KAT is a defi token with governance-like mechanics for Katana.  It is designed to function as a lever for directing capital: users that lock KAT receive a voting version of KAT — vKAT — in return. vKAT underpins key aspects of the chain’s economy, providing rewards to those users that participate. these fee-based rewards function as an incentive for KAT holders to engage in cooperative, positive-sum behavior.

Katana

Katana is trending as traders debate its price action following a recent exchange listing, with the community closely tracking the project's new vKAT tokenomics and ve-style accrual system. While some investors view the asset as a high-potential DeFi utility play, others are expressing caution amidst volatile market movements and discussions regarding future migration plans.

DIEM transforms AI compute from a service you rent into an onchain asset you own: tokenized intelligence. Each Diem token represents $1 per day of Venice API capacity that never expires and never changes value.  DIEM are ERC20 tokens on Base and can be transferred, traded, and staked. DIEM can only be minted by locking staked VVV (sVVV), making DIEM and VVV a foundational assets for onchain AI. Tokenizing intelligence with DIEM creates new possibilities:  Developers/agents: 1 DIEM = $1/day Venice API access, forever VVV holders: Monetize unused compute as DIEM → earn yield → buy back later to unlock VVV Apps: Fixed AI costs, guaranteed capacity, no variable API bills Onchain economy: Agents own their intelligence, DeFi collateralizes compute  Minting DIEM with VVV creates a brand-new onchain building block for AI – programmable, composable compute

Diem

Diem is seeing heightened activity following its listing on Coinbase and ongoing discussions regarding its minting relationship with VVV. Market participants are actively debating the trade-offs between staking strategies and direct token accumulation as the ecosystem scales.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin remains a highly polarized asset on social media, with investors debating its long-term potential amid frustrations over stagnant price action and minimal communication from leadership. While some community members continue to accumulate aggressively, viewing current levels as a strategic buying opportunity for future cycles, others express deep skepticism and frustration regarding its performance relative to the broader crypto market.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community surrounding $UPDOG is actively highlighting the project's longevity on Solana and its presence on the Jupiter strict list, encouraging users to swap via JUP. Traders are also discussing broader market sentiment and utilizing JUP's lending features, despite some community frustration regarding exchange volatility and platform performance.

Magnachip Semiconductor Corp. engages in the design and manufacture of analog and mixed-signal platform solutions for communications, Internet of Things (IoT), consumer, computing, industrial, and automotive applications. Its products include MOSFETs, IGBTs, AC-DC/DC-DC converters, light-emitting diode (LED) drivers, regulators, power management integrated circuits (PMICs), and industrial applications such as power suppliers, e-bikes, photovoltaic inverters, LED lighting, and motor drives. The company was founded on November 26, 2003 and is headquartered in Cheongju-si, South Korea.

MagnaChip Semiconductor Corp

MagnaChip Semiconductor is currently a focal point for investors due to its attractive valuation and active share buyback program, which recently saw an expansion to $87.5 million. The community is actively debating the likelihood of a strategic buyout or merger, particularly with persistent rumors surrounding potential interest from South Korean conglomerates.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Relay Therapeutics Inc

Relay Therapeutics is currently trending as institutional investors and the community weigh the potential for a multi-billion dollar acquisition, driven by the presence of a board experienced in major pharmaceutical buyouts and an upcoming clinical data catalyst in May. Market participants are closely monitoring the high concentration of institutional ownership and a substantial short position, which is fueling intense speculation regarding a potential structural breakout or buyout offer from major industry players like Pfizer or Novartis.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is drawing significant attention as institutional inflows remain robust despite broader market volatility, with the community actively debating whether Bitcoin's resilience amid geopolitical tensions signals a decoupling from traditional risk assets. Traders are closely monitoring heavy options activity and institutional accumulation patterns, as many look for confirmation of a durable bottom.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Down 39.8% in March

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest...

ProShares Ultra Nasdaq Biotechnology Declares Quarterly Dividend of $0.01 (NASDAQ:BIB)

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) announced a quarterly dividend on Tuesday, March 24th. Shareholders of record on Wednesday, March 25th will be given a dividend of 0.0071 per share...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Cross Below 50 Day Moving Average - What's Next?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Cross Below 50 Day Moving Average - Time to Sell...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Below 50 Day Moving Average - Time to Sell?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Share Price Cross Below 50-Day Moving Average - Here's Why...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Down 27.9% in January

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 30th, there was short interest totaling 21,087...

Short Interest in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Declines By 29.2%

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 28,385...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) to Issue Quarterly Dividend of $0.13

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) declared a quarterly dividend on Tuesday, December 23rd. Shareholders of record on Wednesday, December 24th will be paid a dividend of 0.1346 per...

<ul class="summary-bullets"><li>With Abivax now trading as a strategic asset rather than a pure clinical story, takeover interest from a deep-pocketed pharma player introduces a potential valuation floor.</li><li>At roughly an $11 billion market cap, the stock is priced with strong odds of UC success and meaningful commercialization.</li><li>There is still room for upside if Crohn’s disease data validate a broader, multi-indication franchise.</li></ul>French clinical-stage biotech Abivax (ABVX) had an uneventful Nasdaq debut in October 2023 and spent much of its early public life flying under the radar. That changed abruptly this year after a single clinical data readout flipped the narrative — a familiar inflection point in biotech investing.&nbsp;<a href="https://stocktwits.com/symbol/ABVX">Abivax’s stock</a> is up nearly 1,900% year-to-date, making it the best-performing biotech stock&nbsp;on U.S. exchanges.Adding fuel to the mid-year momentum, Eli Lilly (LLY) has emerged as a potential suitor, with market chatter suggesting the pharma giant is circling the smaller biotech. French media outlet La Lettre reported earlier this week that a delegation of Lilly executives met with the French Treasury and&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.lalettre.fr/fr/entreprises_sante/2025/12/22/l-americain-eli-lilly-en-operation-seduction-a-bercy-pour-racheter-la-biotech-abivax,110583257-art">submitted</a> an acquisition proposal for Abivax.How does this shift the investment thesis around this smaller name? What was once a high-beta, data-driven clinical bet increasingly looks like a strategic M&amp;A optionality trade, with a potential floor under the stock—at least in the near term.<img src="https://news.stocktwits-cdn.com/Abivax_since_IPO_png_b0a5af2a71.webp" alt="Abivax since IPO.png">Source: Koyfin<h2 class="st-heading-2">From Clinical Breakout to Strategic Asset</h2>For all the hype around the name, Abivax is still&nbsp;more or less a one-trick pony. Its lone pipeline asset and lead candidate, Obefazimod, is an immunomodulator that is being evaluated for multiple indications. The indication that is&nbsp;most developed is moderately to severely active ulcerative colitis (UC).&nbsp;Obefazimod acts by enhancing the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. Inflammatory Bowel Disease (IBD), a broader term used to refer to chronic conditions such as UC and Crohn’s disease, is an autoimmune response. The immune system mistakenly attacks the gut, causing inflammation and damage to the digestive tract, leading to symptoms such as diarrhea, abdominal pain, weight loss and fatigue.&nbsp;UC affects the large intestine and rectum, causing ulcers on the inner lining, and Crohn’s disease can affect any part of the gastrointestinal tract and inflames the entire bowel wall.&nbsp;Is the condition such a big opportunity? By Abivax’s own account, it seems so. In a corporate presentation, the company said, citing Evaluate data, that IBD prevalence was 3.6 million in the G7 nations in 2024, with roughly 64% in the U.S. The prevalence is expected to grow at a modest 4% pace over the next six years. Worldwide IBD drug sales in 2024 are estimated at $23.7 billion, with 70% from the U.S.<h4 class="st-heading-4" style="text-align:center;">Worldwide IBD Sales&nbsp;</h4><figure class="image"><img style="aspect-ratio:661/535;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_1_48_03_AM_png_2f93920926.webp" alt="Screenshot 2025-12-24 at 1.48.03 AM.png" width="661" height="535"></figure>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; Source: AbivaxThe current treatment options include:-Interleukin-23 selective inhibitors (block the action of pro-inflammatory cytokine protein interleukin-23)-Sphingosine 1-phosphate (S1P) modulators such as ozanimod and etrasimod (target proteins linked to inflammation on immune cells and stop them from leaving the lymph nodes)-Janus Kinase (JAK) inhibitors (stop several types of pro-inflammatory cytokines from forming)Abivax projects Obefazimod as a differentiated treatment option compared to existing therapies, by enhancing the expression of microRNA-124, a natural regulator of the inflammatory response. The mode of administration is also convenient: an oral once-daily pill with a favorable long-term safety profile.<h2 class="st-heading-2">Wall Street Analysts’ Optimism Abounds</h2>Following topline data from two Phase 3 studies showing the candidate met the primary and secondary endpoints, Abivax stock received love from several Wall Street firms, with Morgan Stanley upgrading the stock to an ‘Overweight,’ according to the Fly.&nbsp;The pooled placebo-adjusted clinical remission for the 50mg dose of 16.4% came in above the roughly 15% bar that Morgan Stanley analysts estimated based on their conversations with investors and experts. The analyst also expected improved odds of success across UC and Crohn's.&nbsp; Guggenheim analysts estimated Obefazimod’s value at $7 billion to $10 billion.Piper Sandler analysts said following the Phase 3 data, they have layered in revenue in early-line UC. This doubles its U.S. UC estimate to 2.66 billion euros ($3.14 billion) in 2035, suggesting there could be significant upside to the stock ahead of key data events.Abivax presented the results of the two late-stage studies at the United European Gastroenterology (UEG) Meeting in Berlin in early October. Citizen JMP analysts, who upped their price target ahead of the event, said the data reinforce Obefazimod’s efficacy and increase conviction in its multi-billion-dollar sales potential. Guggenheim named Abivax as a “Best Idea” and upped its price target to $150.&nbsp;Last month, Wolfe Research initiated coverage of the stock with an ‘Outperform’ rating and a $176 price target. The firm based its optimistic assessment on its belief that the company’s odds of success in Crohn’s disease may be higher than those of UC. Crohn’s readout would be a better catalyst in 2026, it added.According to Koyfin, the average analyst price target for Abivax stock is $138.35, implying a 22% downside from current levels. Of the five analysts covering the stock, four have either a ‘Buy’ or a ‘Strong Buy’ rating, and one remains on the sidelines.<h2 class="st-heading-2">Retail Jump Onto Bullish Bandwagon</h2>The Abivax stock stream on Stocktwits has attracted a large following, with the watcher count jumping over 5,500% in the past year. The 30-day message volume is up 2,100%.&nbsp;Retail sentiment toward the stock was ‘extremely bullish’ as of early Wednesday, and it has mainly remained upbeat throughout the year. A bullish&nbsp;<a href="https://stocktwits.com/jeremy0916/message/639921688">watcher</a> has already set his sights on the $230 level for a stock that ended Tuesday’s session at $138.35.<figure class="image"><img style="aspect-ratio:724/433;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_3_01_43_AM_png_3c8d4a0547.webp" alt="Screenshot 2025-12-24 at 3.01.43 AM.png" width="724" height="433"></figure><h2 class="st-heading-2">Key Catalysts Investors Are Watching</h2>Fresh off its addition to the Nasdaq Biotechnology Index, Abivax is entering a catalyst-rich phase. The topline results from an ongoing 44-week maintenance trial, dubbed ABTECT-107, are expected to be read out in the second quarter of 2026. The company also plans to release topline data from the Phase 2 Crohn’s Disease study in the second half of next year.<h2 class="st-heading-2">Why Lilly Might Be Interested</h2>Obefazumod could be a better fit in Lilly’s immunology franchise, which includes Omvoh, an IL-23 inhibitor, used as a second-line treatment for adults with moderately to severely active UC and Crohn’s disease. It is administered as an IV infusion. Lilly also acquired Morphic Pharma, thereby adding an oral integrin blocker for UC.Abivax’s current market valuation is roughly $11 billion. The company’s cash position as of Sept. 2025 is 589.7 million euros, and the company said it has a cash runway into the fourth quarter of 2027.&nbsp;Whether that Lilly deal materializes or not, Abivax enters 2026 with elevated expectations, higher stakes, and far more eyes on the name than ever before.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-s-worst-year-in-four-decades-may-end-thanks-to-a-weight-loss-pill/cLepFr2REuw">Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill</a>

In this photo illustration, the Abivax logo is seen displayed on a smartphone screen.

How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.

Equity

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.


ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average - Here's Why

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Above 50 Day Moving Average - What's Next...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Above 50 Day Moving Average - Time to Sell...

BIB
ProShares Ultra Nasdaq Biotechnology

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest BIB News

BIBProShares Ultra Nasdaq Biotechnology